Utility Analysis for Pegfilgrastim in DLBCL Patients on R-CHOP Regimen
![]() |
Jung, Hee Won
(Graduate School of Clinical Pharmacy, Sookmyung Women's University)
Kim, Jeong Mee (Department of Pharmacy, Samsung Medical Center) Min, Myung Sook (Department of Pharmacy, Samsung Medical Center) Lee, Young Mee (Department of Pharmacy, Samsung Medical Center) Bang, Joon Seok (Graduate School of Clinical Pharmacy, Sookmyung Women's University) |
1 | Hollingshead LM, Goa KL. Recombinant granulocyte colony-stimulating factor (rG-CSF): a review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991;42:300-30. DOI |
2 | Grigg A, Solal-Celigny P, Hoskin P, et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44(9):1503-8. DOI |
3 | Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14(1):29-35. DOI |
4 | Balducci L, Al-Halawani H, Charu V, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007;12(12):1416-24. DOI |
5 | Lathia N, Isogai PK, De Angelis C, et al. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients. J Natl Cancer Inst 2013;105(15):1078-85. DOI |
6 | Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100(2):228-37. DOI |
7 | Author affiliations from The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89(11):3909-18. |
8 | Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States 1992-2001. Blood 2006;107(1):265-76. DOI |
9 | Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network. Br J Cancer 2011;105(11):1684-92. DOI |
10 | Freeman AS, Aster JC. (2012) Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma. In basow, Denise S. UpToDate: (http://www.uptodate.com/contents/epidemiology-clinical-manifestations-pathologic-features-and-diagnosis-of-diffuse-large-b-cell-lymphoma) |
11 | Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the RCHOP study in the treatment of elderly patients with diffuse large Bcell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23(18):4117-26. DOI |
12 | Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346(4):235-42. DOI |
13 | Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29(3):319-24. DOI |
14 | Bennett CL, Djulbegovic B, Norris LB, et al. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med 2013;368(12):1131-9. DOI |
15 | McEvoy G. AHFS Drug Information. 2012. |
16 | Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 Published May 28, 2009 by National Cancer Institute (http://www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20-%20DMCC.pdf) |
17 | Health Insurance Review & Assessment Service www.hira.or.kr; (Accessed on October 2014). |
18 | Amgen. NEUPOGEN (filgrastim) Prescribing Information. http://www.amgen.com; (Accessed on October 2014). |
![]() |